Medgenics Reports 2013 Financial Results

WAYNE, Pa. and MISGAV, Israel, Feb. 20, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT: MDGN) (LSE:MEDU) (LSE:MEDG), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced financial results for the fiscal year ended December 31, 2013 and the filing with the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Annual Report on Form 10-K.

This entry was posted in Recent Development News: Q1 - 2014. Bookmark the permalink.